INTRODUCTION:

The primary liver cancer that occurs most frequently is Hepatocellular Carcinoma (HCC). HCC, often known as liver cancer it is the development and spread of uncontrolled malignant cells in the liver and occurs most often in people with chronic liver diseases, such as cirrhosis caused by Hepatitis B or Hepatitis C infection.¹Globally, HCC is the dominant type of Hepatic malignancy, accounting for ~75% of all hepatic malignancy.^2,3In 2018, the estimated global incidence rate of hepatic malignancy per 100,000 person-years was 9.3 whereas the corresponding mortality rate was 8.5.³The incidence rate of HCC in India for men ranges from 0.7 to 7.5 and for women 0.2 to 2.2 per 100,000 population/year. The male:female ratio for HCC in India is 4:1.^4,5This Review summarizes the magnitude of the HCC problem, current scientific knowledge of the treatment of HCC, outstanding challenges and potential opportunities for of this prominent human disease.

Etiology and Risk Factors:

Several common and important risk factors associated with development of HCC are such as, Chronic Viral Hepatitis, Cirrhosis, Non- Alcoholic Fatty Liver, Aflatoxin ingestion and Alcohol consumption, i.v. drug abuse, metabolic disease like Obesity, Diabetes, Hypertension. etc.

Chronic Liver Disease and Cirrhosis:

Chronic viral Hepatitis can lead to cirrhosis and/or HCC. Hepatitis B and C are the most common causes of chronic Hepatitis in the world.⁶Hepatitis B surface antigen (HBsAg) is hematological markers that carries a significant risk for development of HCC. Research study done by Hosaka T. reported that,Hepatocarcinogenicity of HBV can be significantly reduced with antiviral treatment for Hepatitis B. Suppression of the virus can results in a significant 5-year reduction of the incidence of HCC from 13.7% (controls) to 3.7%, with the greatest reduction occurring in cirrhotic patients.⁷ Once infected with HCV, 80% of patients progress to chronic Hepatitis C, with ~20% developing cirrhosis.⁸ In Hepatitis C, the development of HCC occurs almost exclusively in the liver with established cirrhosis; however in HALT-C trial, 8% of HCC occurred in patients with only advanced fibrosis.⁹

Alcohol:

The relationship between Alcohol and liver disease correlates with the amount of Alcohol consumed over a lifetime, with heavy Alcohol use (>3 drinks per day) rather than social drinking being the main risk of HCC.^10,11

Diabetes and Non-Alcoholic Fatty Liver:

Chronic medical conditions such as Diabetes Mellitus (DM) and obesity increases the risk of HCC. Diabetes is an independent risk factor for HCC disease. DM directly affects the liver because of the essential role the liver plays in glucose metabolism. It can lead to chronic Hepatitis, Fatty liver, Liver failure, and Cirrhosis. Pleotropic effect of Insulin regulates anti-inflammatory cascade and other pathways inducing cellular proliferation play a role in carcinogenesis. Insulin-like growth factor and insulin receptor substrate-1 promotes cellular proliferation and inhibit apoptosis, respectively.^12,13

Gender:

Testosterone is a male sex hormone. Studies suggest that may be the higher testosterone levels that account for the higher incidence of HCC in males. It is known that high testosterone levels have been linked to HCC in Hepatitis B carriers and t1o advanced hepatic fibrosis in males with chronic Hepatitis C infection. Elevated testosterone or intake of anabolic steroids has been associated with an increased incidence of HCC and liver adenomas.^14,15

Aflatoxin:

A strong hepatocarcinogen, aflatoxin is formed by Aspergillus species (moulds) found on grains, corn, peanuts, and soybeans stored in warm, humid environments. Aflatoxin exposure duration and dose affect the chance of developing HCC. Aflatoxin exerts a synergistic effect on Hepatitis B- and C-induced liver cancer.The risk being 30 times greater with chronic Hepatitis B plus aflatoxin exposure than with aflatoxin exposure alone.¹⁶

Pathology of HCC:

Aflatoxin-B1-induced HCC:

As well as being connected to a particular p53 mutation16,52–55 and collaborating mutational activation of oncogenes like Harvey Rat sarcoma virus (HRAS), Aflatoxin B1 appears to have mutagenic properties. Additionally, oxidative stress, continual cycles of necrosis and regeneration, and genetic changes are all common and can be resulting in HCC.¹⁸ Figure No.1.

Viral-induced HCC:

The impact of HBV infection on HCC development is reflected by the correlation between increased incidence of HCC in patients with increasing levels of HBV DNA in serum and may lead to expanded or altered stem cell compartment of hepatocarcinogenesis. One possibility relates to HBV's capacity to integrate into host genomes (in contrast to HCV), leading to changes in genes related to cancer.¹⁹ HBV- and HCV-related hepatocarcinogenesis is characterised in particular by p53 inactivation, inflammation, ongoing cycles of necrosis and regeneration, and oxidative stress. suggesting that these processes play a crucial role in the development of HCC. Both HBV and HCV activate the MAPK pathway, which also indicates its pathogenetic relevance.²⁰ Figure No.1.

Alcohol-Induced HCC:

Alcohol consumption corelated with increased oxidative stress, inflammation and cirrhosis, which are responsible for possible mutagenic effect and disturbance in necrosis and regeneration balance leads genetic alterations resulting in HCC.²¹ Figure No.1.

Figure No. 1: General Molecular Pathology of HCC¹⁷

Clinical Signs and Symptoms of HCC:

Right Shoulder Blade pain:

Shoulder-blade pain can be a sneaky symptom. The tumor(or spread from the tumor) can irritate nerves.This pain is typically felt in the right shoulder, though it may occur on either side. Pain, discomfort, or aching on the right side of the abdomen just under the ribsmay occur due to the pressure of a liver tumor on other structures or nerves in this region.^22,23

Palpable Liver Mass:

A palpable liver can be felt during examination of the abdomen. A palpable liver may therefore be normal if the liver edge is felt 2 cm below the right lower rib edge or abnormal if, the lower liver margin is felt 14 cm down.²³

Bloat and Shortness of Breath:

Fluid build-up in the abdomen referred to as ascites can be indicate liver cancer. It may feel like bloating at lung causing shortness of breath.²³

Unintentional Weight Change:

Usually occurs due to the rapid build-up of fluid in the abdomen (ascites).²³

Gastric Disturbances:

The mechanism responsible for the loss of appetite in liver cancer is the build-up of toxins in the body. Malignancy causes the liver to have a diminished ability to filter and breakdown toxins in the blood. This toxicity impacts on digestive physiology causes multiple digestive symptoms, including nausea, vomiting and anorexia.²³

Diagnosis of HCC:

History and Clinical Examinations:

Symptoms and signs of chronic liver disease (Jaundice, Ascites, Encephalopathy, Bleeding, Splenomegaly). Peripheral Smear (PS) (distinguish cancer-related symptoms of recent onset with long-standing symptoms associated with cirrhosis) and nutritional state.²⁵

Etiological Factor of Liver Disease:

Finding of responsible etiological factors such as, HBV (HBsAg and anti-HBc), HCV (anti-HCV), iron status, autoimmune disease is likely for development of HCC, which gives early assessment/diagnosis for HCC.²⁵

Laboratory Analysis:

a) Liver Function Test:

Liver function tests (LFTs or LFs) includes prothrombin time (PT/INR), activated Partial Thromboplastin Time (PTT), albumin and bilirubin (direct and indirect), SGPT (Serum Glutamic Pyruvic Transaminase), SGCT (Symmetric Gate-Commutated Thyristor), Bilirubin, ALP (Alkaline Phosphate), AST (Aspartate Aminotransferase).²⁵

b) Tumor Biomarkers:

As from complete Blood Cells count is not provide prominent diagnosis for HCC, but the use of Biomarkers available in Blood Plasma provides definite results for diagnosis results for diagnosis of HCC.

AFP (Alpha-FetoProtein):

There have been several investigations concerning the diagnostic utility of AFP suggesting that elevated serum AFP levels (>20ng/mL) correlate with an increased risk for HCC development. Although the sensitivity of AFP is excellent, its specificity is low.^24,25AFP shows low sensitivity because it is not overexpressed in all HCC patients. It was found that elevated AFP levels were not evident in around 80% of small HCCs.

DCP (Des-gamma-Carboxy-Prothombin):

Abnormal prothrombin molecule induced due to vitamin-K deficiency (PIVKA-II) and posttranslational carboxylation machinery is known as DCP. DCP is an abnormal prothrombin molecule overproduced in HCC patients. This marker is not used for early detection of HCC. DCP levels have been associated with portal vein invasion and advanced stage of HCC as with AFP fraction level.^26,27

Combination of AFP, AFP-L3, DCP Markers:

At present, the combination of AFP+AFP-L3+DCP is included in the diagnostic algorithm of hepatic nodules by Oriental guidelines for HCC management, but not by Western guidelines.^26,27

Other Biomarkers (GPC3,GS,HSP70):GPC3 is a cell-surface proteoglycan of the glypican family. This proteoglycan is overproduced in HCC cells and plays a pivotal role in regulating tumor growth.This marker is similar to AFP, showed high specificity but low sensitivity.²⁸

Novel Biomarkers For HCC:

For clinical need necessary to discover better biomarkers for HCC that (I) fully correlate with the tumor stage; (II) can be detected in early HCC; and (III) allow for tumor surveillance and evaluation of therapeutic efficacy.²⁹

CK19:

CK19 is a novel HCC biomarker associated with poor prognostic factors in HCC patients due to high risk of microvascular invasion and distant metastasis, as well as worse treatment outcome.³⁰

GP73:

GP73 is a transmembrane protein localized in the Golgi complex. Although it is absent in normal hepatocytes, abundantly overexpressed in HCC patients, compared with cirrhotic patients. GP73 could be used as a marker in early-stage.³¹

OPN:

OPN is a glycoprotein, an extracellular matrix proteinexpressed in HCC cells and other various types of malignancies. OPN, although, it has a higher sensitivity in the discrimination of early HCC than AFP according to the clinical study.Therefore, combination with AFP is necessary to optimize its performance.³²

SCCA:

SCCA is a serine protease inhibitor. It is found in squamous epithelium. The use of SCCA as an additional diagnostic marker with AFP for HCC has been well documented. Also, it might play a role as a biomarker for response to treatment as there is an inverse correlation with the treatment response for HCC. Finally, the combination of AFP and SCCA should be investigated in future studies to validate the diagnostic role of SCCA as a predictor for the risk of HCC in patients with chronic liver disease.³³

Annexin A2:

Annexin A2 is a calcium-dependent, phospholipid-binding protein. It is present in the cell surface, and it seems to be implicated in the development and metastasis of HCC. It has been used as a serological biomarker for diagnosis and prognosis of early-stage HCC patients with higher sensitivity and specificity than AFP.³⁴

miRNA:

miRNAs are small non-coding endogenous RNAs that have been implicated in various biological roles at the cellular level including apoptosis and oncogenesis. There are several types of miRNAs being tested as diagnostic and prognostic markers for HCC.³⁵

lncRNAs:

Accumulating evidence showed that dysregulatedlncRNA had been involved in the pathogenesis of HCC. Lately, IncRNA has been recognized as important regulators for carbohydrate and lipid metabolism; this has led to discovering a novel biomarker “IncRNAFtx” which stimulate HCC progression and glycolysis.^36,37

CTCs:

Detection of CTCs is associated with poor overall survival and relapse-free survival. In addition to that, CTCs positivity is significantly correlated with serum AFP level, vascular invasion and TNM stage which can reflect the histopathological status of HCC.³⁸

cfDNA:

Dysregulated levels of cfDNA have a role in diagnosis, monitoring of treatment response, and even outcome prediction for cancer diseases.³⁹

c) Imaging Studies:

Liver dynamic (multiple phase) MRI/CT studies for diagnosis and evaluation of tumour extent inside the liver (number and size of nodules, vascular invasion, extrahepatic spread), CEUS can also be used for the non-invasive diagnosis of HCC if CT scan or MRI are not possible, but is not considered appropriate for tumour staging, CT of the chest, abdomen and pelvis to rule out extrahepatic spread.²⁵

d) Ultrasound:

An Ultrasound uses sound waves to create a picture of the structures inside the body, using a small amount of radiation. The sound waves bounce off the liver, other organs, and tumors. Each creates a different picture on a computer monitor.⁴⁰

e) Computed Tomography (CT) Scan:

HCC can be diagnosed based on features specific to the cancer that are seen on a CT scan. Compared with multiple detector CT (MDCT), multiphasic MRI offers a moderate increase in sensitivity for diagnosing HCC based on the typical vascular hallmarks [III,B].^41,42

f) Magnetic Resonance Imaging (MRI):

The use of hepatobiliary contrast agents, MRI may identify and stratify nodules as high-risk nodules (either HCC not displaying the typical imaging hallmarks features or high-grade dysplastic nodules) [IV,B].⁴¹

g) PET-CTScan (Positron Emission Tomography):

In the PET scan, patient injected in the armwith a glucose solution containing a small amount of radioactive material. After 30–90 minutes whole body scanned for raised levels of radioactive glucose. Cancer cells show up brighter on the scan pictures because they are more active and take up more of the glucose solution than normal cells. Angiography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scan are not recommended for HCC diagnosis.^41,42

h) Biopsy:

A biopsy or surgical specimen of the tumour is used to provide a pathological diagnosis of HCC. It should address different challenges: morphologically, highly differentiated HCC must be distinguished from benign/ premalignant lesions (dysplastic nodules, hepatocellular adenoma, focal nodular hyperplasia). Evaluation of the resection margin as well as the explant specimen is done in accordance with the accepted TNM (tumour, node, metastasis) classification. Typically, a tumour grade is given, although no universal grading system is now in use around the world, and data regarding the independent prognostic significance are still ambiguous.⁴² Figure No.2.

Figure No. 2: Histological Analysis of HCC⁴³

Staging of HCC:

TNM Staging Classification⁴⁵:

Primary Tumor (T): TX - the primary tumour cannot be measured; T0: The primary tumour cannot be located; T1, T2, T3, and T4: Describes the size and/or extent of the primary tumour. The size of the tumour or the extent of its invasion into neighbouring tissues is indicated by the number after the T. To provide further information, Ts can be further separated into T3a and T3b.

Regional Lymph Nodes (N): NX, It is impossible to gauge the presence of cancer in surrounding lymph nodes.N0: The lymph nodes in the area are cancer-free; N1, N2, and N3: Indicates the quantity and location of lymph nodes that are cancerous. The more cancerous lymph nodes there are, the higher the number following the N.

Distant Metastasis (M): MX, Metastasis cannot be quantified.M0: The cancer has not spread to other body regions; M1: The cancer has spread to additional body locations.

BCLC Staging Classification:

The Barcelona-Clínic Liver Cancer (BCLC) staging system was constructed on the basis of the results obtained in the setting of several cohort studies and RCTs by the Barcelona group. Patients at stage A with early HCC are candidates for radical therapies (resection, liver transplantation or percutaneous treatments). Patients at stage B with intermediate HCC may benefit from chemoembolization. Patients at stage C with advanced HCC may receive new agents in the setting of RCT, and patients at stage D with end-stage disease will receive symptomatic treatment.⁴⁶

Union for International Cancer Control (UICC) Staging:

The Union for International Cancer Control (UICC) classification has been Know the general principles of the UICC TNM Classification of Malignant Tumours. This classification provides a seven-stage classification system as IA, IB, II, IIIA, IIB, IVA and IVB.⁴⁶

Okuda Stage:

Albumin, ascites, bilirubin, and tumour stage with involvement of more than 50% of liver area are some of the characteristics related to the liver function status that are included. Considering that the majority of the patients had advanced or symptomatic diagnoses, this classification effectively categorised the patients. To evaluate the potential benefits of new treatment drugs and exclude end-stage patients (Okuda stage III) due to their poor prognosis, it is helpful to identify these patients. This classification provides a three-stage classification as I, II and III.⁴⁴

French Classification:

The French classification combines fives variable in a score system that stratified Patient in the three stages. Recent research comparing it to other staging systems has revealed that it only has a limited ability to predict outcomes in patients with early HCC. This classification provides a scoring classification as A: 0point, B: 1-5 point and C: >6 points.⁴⁴

Cancer of the Liver Italian Program (CLIP score):

Four different factors are combined to get a score that has seven stages. With better discriminatory power, it has been compared with the Okuda stage and the TNM stage. A scoring classification system is provided by this categorization. The numbers are 0 through 6.⁴⁴

Chinese University Prognostic Index (CUPI):

The Chinese University Prognostic Index (CUPI) separated patients into three stages and took into account six predicted variables. In comparison to Okuda stage and CLIP score, the author believes that this categorization provides a more accurate prediction of survival. This classification are provide a scoring classification as I) Low risk:Score1, II) Intermediate: Score 2-7 and III) High: Score>8.⁴⁴

Japan Integrated Staging (JIS):

The Japan Integrated Staging (JIS) is a new score system that include two previous classifications. The TNM endorsed by the Union International Centre Le Cancer (UICC).This classification provides4-stage classification as I, II, III and IV.⁴⁴

Treatment of HCC:

Trans Arterial Chemoembolization:

One of the most widely utilised nonsurgical treatments for HCC is currently recognised as Trans Arterial Chemoembolization (TACE).

a) Basic Principles for TACE:

It is essential to establish highly targeted catheterization of tumor-feeding artery branches. The patient's liver function needs to be appropriately reserved. The procedure must be carried out in an uniform yet customised way.Switching to or combining with other treatments such as surgery, local ablation, systemic treatment and radiation therapy should be considered if the tumor still continues to progress after 3–4 sessions of TACE.⁴⁷

b) Indications for TACE:

Patients with Stage IIIb illness with CNLC Stage IIb and IIIa HCC with Child-Pugh Grade A or B and a PS score of 0 to 2. Patients with Stage Ib and IIaresectable CNLC HCC who are unable or unable to have surgery due to other factors including advanced age or severe cirrhosis. Patients with partial obstruction of the main portal vein, creation of several compensating collateral vein branches, or recanalized portal vein via portal vein stenting despite total obstruction. DSA can be performed for early detection of residual cancer or recurrent lesions following liver resection and TACE can be performed as appropriate.⁴⁷

c) Contraindications for TACE:

Irreversible severe coagulation malfunction ongoing hepatitis or a serious infection is there, then it cannot be treated concurrently. Distal widespread metastasis with an anticipated survival time of three months. Patients who are experiencing cachexia or multiple organ failure cannot be performed. Tumor load >70% of the liver's overall volume. There is a considerable decrease in peripheral white blood cell (WBC) and platelet counts, with a WBC level of 3.0 109/L and a platelet level of 50 109/L, respectively. Renal insufficiency: blood Cr >2 mg/dL or blood Cr clearance rate <30 mL/min.⁴⁷

Local Ablation:

Locoregional ablation provides opportunities for radical treatment in patients with early HCC unsuitable for surgical resection. Ablation can be performed through a percutaneous, laparoscopic, or laparotomic approach. Most HCC lesions can be percutaneously ablated, which has advantages of cost-effectiveness, ease of use, and minimal invasiveness.^48,49

a) Radiofrequency Ablation (RFA):

RFA uses high-energy radio waves. RFA is a commonly used minimally invasive ablation method for HCC and has advantages, including ease of use, short hospital stay, excellent efficacy, and good control over the ablation range. This procedure is particularly suitable for older patients and patients with comorbid diseases, severe cirrhosis, tumors located in deep positions in the liver, or central HCC. RFA has significant advantages including a higher radical cure rate, fewer sessions of treatment, and higher long-term survival rates compared with PEI. The essence of RFA is to ablate the tumor as a whole and maintain a sufficient safety margin while minimizing the damage to normal liver tissues.⁵⁰

b) Microwave ablation (MWA):

MWA is another commonly used thermal ablation method, which is characterized by high efficiency, short ablation time, and reduced heat-sink effect as compared with RFA. For large tumors with rich blood supply and adjacent to large blood vessels, MWA has advantages, including short treatment time and little influence by vascular heat sinks. MWA also provides treatment opportunities for elderly patients unable to tolerate lengthy anaesthesia and patients who previously received stent or pacemaker implantation. The selection of MWA or RFA should be based on the size and position of tumor, and the operator’s experience.⁵¹

c) Percutaneous Ethanol Injection (PEI):

PEI is suitable for tumors with a diameter of ≤3 cm. PEI has good ablative effects and similar long-term efficacy to RFA for tumors with a diameter of ≤2 cm despite having a higher local recurrence rate versus RFA [146] (level 1 evidence). The advantage of PEI lies in its safety and is in particular suitable for tumors in high-risk locations such as lesions near the hepatic hilar region, gallbladder, and gastrointestinal tracts. However, repeated PEI procedures are required.⁵²

Surgical treatment:

Surgical treatment provides the best opportunity for achieving long-term survival in HCC patients and is mainly comprised of hepatectomy and liver transplantation.⁵³ In most cases, surgical resection is not superior to non-surgical approaches such TACE in patients with CNLP stage IIb HCC. In patients with tumor-thrombi in the main trunk or branches of the portal vein, surgical removal of the tumor and embolectomy through the portal vein can be considered, followed by postoperative TACE.⁵⁴

a) Basic Principles for Hepatectomy: Thoroughness:

Complete removal of tumour tissue, making sure there is no remaining tumour at the surgical margin.Safety: Preservation of a sufficient volume of functional liver tissue (with good blood supply and blood and bile outflow) to compensate liver function and reduce surgical complications and postoperative mortality.⁵³

b) Criteria for Curative Resection:

The hepatic vein, portal vein, bile duct, and inferior vena cava do not contain any macroscopic tumour thrombi.In the absence of distant metastases, portal lymph node involvement, or neighbouring organ involvement.The distance between the surgical margin and tumor boundary is >1 cm or histologic examination of the cross section of the resected liver is free of residual tumor cells, that is, negative surgical margin, if the surgical margin is <1 cm.⁵⁵

Liver Transplantation:

All of the criteria for transplantation agree on factors, including the absence of macrovascular involvement, lymph node metastasis, and extrahepatic metastasis, but diverge in classification by the size and number of tumors. These domestic criteria expand indications for liver transplantation for HCC to enable a greater number of HCC patients to benefit from liver transplantation without significantly reducing postoperative overall survival and tumor free survival.⁵⁶Liver transplantation is a radical treatment approach for HCC and is particularly suitable for patients with compensated liver function. It is recommended that the UCSF criteria are followed as the Chinese criteria for the indication of liver transplantation for HCC. Early withdrawal of or no use of hormone-containing regimens, dose reduction of calcineurin inhibitors in the early posttransplant period and use of immunosuppressive therapy with mTOR inhibitors such as rapamycin and everolimus after liver transplantation may also be associated with reduced tumor recurrence and improved survival rates.⁵⁷

Recent Advances in Hcc Treatment:

Nanotechnology:

Cancer nanotechnology is one such area of works which involves biology to chemistry, medicine, engineering, and has emerged as a new field of development.⁵⁸Nanoparticles have unique qualities due to their small size that make them particularly valuable for imaging in oncology. When combined with MRI (magnetic resonance imaging), quantum dots (nanoparticles having quantum confinement qualities such as size-tunable light emission) can competitive differentiation images of tumour locations. These nanoparticles require a single light source for excitation and are far brighter than organic dyes.⁵⁹ Nanotechnology has gained extensive attention in HCC surveillance, imaging and pathological diagnosis, and therapeutic strategies. Furthermore, strategies of facilitating drug release and delivery in current treatment processes such as ablation, systematic therapy, transcatheter arterial chemoembolization, molecular targeted therapy, and immune-modulating therapy have also been studied widely.⁶⁰Noble metal Nanoparticles in particular, are the agents with some biomedical applications including their use in highly sensitive diagnostic assays, thermal ablation, and radiotherapy enhancement, as well as drugand gene delivery.⁶¹Modern procedures allow for more cost-effective nanoparticle preparation, while characterisation technologies allow for comprehensive identification and stability testing. As a result, the future of drug delivery systems will be entirely focused on nanotechnology for the effective and precise treatment of diseases with reduced side effects and dose reduction to a considerable extent.⁶²

Targeted Drug Therapy:

For almost a century, conventional immunotherapy has been used to treat tumours without results. This field is expanding quickly, beginning with Dr. E. Klein's early trials in 1969 that produced hopeful results for the treatment of human skin cancer via an allergic reaction. Immunochemotherapy, which involves administering a chemical coupled with an antibody, is becoming more and more popular because it can selectively destroy tumour cells while sparing the host's normal cells. Serious clinical research was impossible before to 1980 because purified analogues of interferons, interleukins, tumour necrosis factor (TNF), and other lymphokines were not yet available.⁶³Targeted therapy is drug treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and limits damage to healthy cells.⁴⁰By focusing on molecular and cellular changes that are specific to cancer, targeted cancer therapies are more effective than other type of treatment chemotherapy and radiotherapy and less harmful to normal cells targeted cancer therapies interfere with cancer cell division and spread in different ways.⁶⁴Tumor immunotherapy refer to the use of the immune defence mechanism of the body to enhance the antitumor immune response and overcome the immune escape of the tumor immunotherapy manifests itself primarily in the immune checkpoint (ICP) inhibitor (ICI), and is mainly represented by tumor vaccine therapy (dendritic cell [DC] vaccine and oncolytic virus vaccine), and adoptive cell therapy (ACT); among them, ICI therapy is of particular concern and has achieved positive result.^65,66 The mechanism of tumor immune escape have been intensively explored.⁶⁷Tumors can include and establish a tumor microenvironment (TME) conductive to immunosuppression, including immunosuppressive cell and molecules, resulting in the loss of antitumor function of T cells and triggering immune escape. Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are the most important components of immunosuppressive cells.⁶⁸ICP offers new hope to patients with advanced HCC.⁶⁹ The latest research on the mechanism and clinical application of ICIs in the occurrence and development of HCC. New biomarkers for predicting treatment response are described, and the future direction of ICP therapy has been prospected. Several Targeted Drug therapy are Bevacizumab, Lenvatinib, Sorafenib, Ramucirumab, Cabozantinib, Regorafenib.

CONCLUSION:

The best course of treatment for hepatocellular cancer relies on its stage, reserved liver function, and multidisciplinary approach. If the proper precautions are implemented, such as hepatitis B virus vaccine, widespread blood product screening, the use of safe injection techniques, treatment and education for alcoholics and intravenous drug users, and the start of antiviral therapy, HCC can be avoided.

CONFLICT OF INTEREST:

The authors have no conflict of interest to declare for this publication.

REFERENCES:

1. Hepatocellular carcinoma - Overview - Mayo Clinic [Internet]. Mayoclinic.org. 2022 [cited 8 August 2022]. Available from: https://www.mayoclinic.org/diseases-conditions/hepatocellular-carcinoma/cdc-20354552

2. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014 Apr 21;20(15):4115-27. doi: 10.3748/wjg.v20.i15.4115.

3. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 Jan;73Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288.

4. Acharya SK. Epidemiology of hepatocellular carcinoma in India. J ClinExpHepatol. 2014 Aug;4(Suppl 3):S27-33. doi: 10.1016/j.jceh.2014.05.013.

5. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25(2):143-54. doi: 10.1055/s-2005-871194.

6. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.

7. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013 Jul;58(1):98-107. doi: 10.1002/hep.26180.

8. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. SurgClin North Am. 2013 Dec;93(6):1423-50. doi: 10.1016/j.suc.2013.08.008.

9. Lok AS, SeeffLB, Morgan TR, et.al. incidence of hepatocellular carcinoma and associated risk factor in hepatitis C- related advanced liver disease. Gastroenterology2009;136(1):138-148.

10. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Alcohol 1998;44(44):207–215.

11. Batey RG, Burns T, Benson RJ, Byth K. Alcohol consumption and the risk of cirrhosis. Med J Aust. 1992 Mar 16;156(6):413-6. doi: 10.5694/j.1326-5377.1992.tb139846.x.

12. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev. 1998 Apr;7(2):89-107.

13. Balkau B, Kahn HS, Courbon D, Eschwège E, Ducimetière P; Paris Prospective Study. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care. 2001 May;24(5):843-9. doi: 10.2337/diacare.24.5.843.

14. Yuan JM, Ross RK, Stanczyk FZ, Govindarajan S, Gao YT, Henderson BE, Yu MC. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer. 1995 Nov 15;63(4):491-3. doi: 10.1002/ijc.2910630405.

15. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012 Mar;55(3):759-68. doi: 10.1002/hep.24618. Epub 2011 Dec 14.

16. hen JG, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu YR, Qian GS, Wu F, Yuan JM, Groopman JD, Kensler TW. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila). 2013 Oct;6(10):1038-45. doi: 10.1158/1940-6207.CAPR-13-0168.

17. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006 Sep;6(9):674-87. doi: 10.1038/nrc1934.

18. Riley J, Mandel HG, Sinha S, Judah DJ, Neal GE. In vitro activation of the human Harvey-ras proto-oncogene by aflatoxin B1. Carcinogenesis. 1997 May;18(5):905-10. doi: 10.1093/carcin/18.5.905.

19. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73. doi: 10.1001/jama.295.1.65.

20. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003 Aug 11;22(33):5093-107. doi: 10.1038/sj.onc.1206557.

21. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002 May;27(1):63-8. doi: 10.1016/s0741-8329(02)00215-x.

1. Fayed, L. (n.d.). Symptoms of liver cancer. Verywell Health. Retrieved September 10, 2021, from https://www.verywellhealth.com/liver-cancer-symptoms-514170.

22. Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? HepatobiliarySurgNutr. 2014 Dec;3(6):410-4. doi: 10.3978/j.issn.2304-3881.2014.07.06.

23. Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015 Feb 27;7(2):139-49. doi: 10.4254/wjh.v7.i2.139.

24. Omata, M., Cheng, AL., Kokudo, N. et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 11, 317–370 (2017). doi: 10.1007/s12072-017-9799-9.

25. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003 May;37(5):1114-21. doi: 10.1053/jhep.2003.50195.

26. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014 Mar;49(3):555-63. doi: 10.1007/s00535-013-0883-1.

27. Xu C, Yan Z, Zhou L, Wang Y. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. J Cancer Res ClinOncol. 2013 Aug;139(8):1417-24. doi: 10.1007/s00432-013-1458-5.

28. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003 Jan;37(1):198-207. doi: 10.1053/jhep.2003.50022.

29. Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, Chen F, Xia H, Lv F, Zhang S, Sun L. CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection. PLoS One. 2016 Mar 15;11(3):e0151501. doi: 10.1371/journal.pone.0151501.

30. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS, Block TM. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005 Dec;43(6):1007-12. doi: 10.1016/j.jhep.2005.05.028.

31. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012 Feb;55(2):483-90. doi: 10.1002/hep.24703.

32. Pozzan C, Cardin R, Piciocchi M, Cazzagon N, Maddalo G, Vanin V, Giacomin A, Pontisso P, Cillo U, Farinati F. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC). J GastroenterolHepatol. 2014 Aug;29(8):1637-44. doi: 10.1111/jgh.12576.

33. Sun Y, Gao G, Cai J, Wang Y, Qu X, He L, Liu F, Zhang Y, Lin K, Ma S, Yang X, Qian X, Zhao X. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma. Carcinogenesis. 2013 Mar;34(3):595-604. doi: 10.1093/carcin/bgs372.

34. Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res. 2015 Jan;45(2):128-41. doi: 10.1111/hepr.12386.

35. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al, FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. Science. 2005 Sep 2;309(5740):1559-63. doi: 10.1126/science.1112014.

36. Sun J, Bie B, Zhang S, Yang J, Li Z. Long non-coding RNAs: critical players in hepatocellular carcinoma. Int J Mol Sci. 2014 Nov 7;15(11):20434-48. doi: 10.3390/ijms151120434.

37. Sun C, Liao W, Deng Z, Li E, Feng Q, Lei J, Yuan R, Zou S, Mao Y, Shao J, Wu L, Zhang C. The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2017 Jul;96(29):e7513. doi: 10.1097/MD.0000000000007513.

38. García-Olmo DC, Domínguez C, García-Arranz M, Anker P, Stroun M, García-Verdugo JM, García-Olmo D. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010 Jan 15;70(2):560-7. doi: 10.1158/0008-5472.

39. Liver Cancer - Types of Treatment [Internet]. Cancer.Net. 2022 [cited 23 September 2021]. Available from: https://www.cancer.net/cancer-types/liver-cancer/types-treatment

40. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.

41. Tests [Internet]. Cancer Council NSW. 2022 [cited 15 September 2021]. Available from: https://www.cancercouncil.com.au/liver-cancer-secondary/diagnosis/tests/#PET-CT

42. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7(1):35-41. doi: 10.1080/13651820410024058.

43. Keliher EJ, Reiner T, Earley S, Klubnick J, Tassa C, Lee AJ, et al; Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia. 2013 Jul;15(7):684-93. doi: 10.1593/neo.13276.

44. Cancer Staging [Internet]. National Cancer Institute. 2022 [cited 29 September 2021]. Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/staging

45. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002 May;122(6):1609-19. doi: 10.1053/gast.2002.33411.

46. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, et al; Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998 Jul;29(1):129-34. doi: 10.1016/s0168-8278(98)80187-6.

47. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al; A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8. doi: 10.1097/01.sla.0000201480.65519.b8.

48. Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al; A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012 Oct;57(4):794-802. doi: 10.1016/j.jhep.2012.05.007.

49. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009 Feb;49(2):453-9. doi: 10.1002/hep.22648.

50. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, et al; Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002 May;223(2):331-7. doi: 10.1148/radiol.2232010775.

51. Di Vece F, Tombesi P, Ermili F, Maraldi C, Sartori S. Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects: a prospective pilot study. CardiovascInterventRadiol. 2014 Jun;37(3):723-9. doi: 10.1007/s00270-013-0733-9.

52. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014 Aug;260(2):329-40. doi: 10.1097/SLA.0000000000000236.

53. Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann SurgOncol. 2010 Aug;17(8):2073-80. doi: 10.1245/s10434-010-0940-4.

54. Li XL, Zhu XD, Cai H, Li Y, Zhou J, Fan J, et al; Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. Surgery. 2019 Jun;165(6):1161-1167. doi: 10.1016/j.surg.2019.01.009.

55. Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl. 2018 Mar;24(3):369-379. doi: 10.1002/lt.24977.

56. Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol. 2018 Dec 7;24(45):5081-5094. doi: 10.3748/wjg.v24.i45.5081.

57. Recent advances in bionanomaterials for liver cancer diagnosis and treatment [Internet]. 2021[cited 29 September 2021] Available from: https://pubmed.ncbi.nlm.nih.gov/34032223/

58. Indranil Singh. A Review on in-Vivo Imaging of Cancer Cells by Bioconjugated Quantum Dots. Asian J. Pharm. Res. 2018; 8(4): 243-248. doi: 10.5958/2231-5691.2018.00042.4

59. Kalyankar T. M., Butle S. R., Chamwad G. N. Application of Nanotechnology in Cancer Treatment. Research J. Pharm. and Tech. 5(9): September 2012; Page 1161-1167.

60. Qi X, Lam SS, Liu D, Kim DY, Ma L, Alleruzzo L, et al; Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer. J Clin Cell Immunol. 2016 Aug;7(4):438. doi: 10.4172/2155-9899.1000438.

61. Avinash B. Thalkari, Pawan N. Karwa, Priyanka S. Chopane, Nareshkumar R. Jaiswal. Nanotechnology: The Future of Cancer. Asian J. Pharm. Tech. 2019; 9(1):40-48. doi: 10.5958/2231-5713.2019.00008.4

62. Rahul Krishnan P R, Sivakumar R. Nanotechnology: Modern Formulation and Evaluation Techniques - An Overview. Research J. Pharm. and Tech 2019; 12(8): 4039-4044. doi: 10.5958/0974-360X.2019.00696.6

63. DibyajyotiSaha, TarashankarMaity, Mayukh Jana, SupradipMandal. Cancer Treatment Strategy-An Overview. Asian J. Pharm. Tech. 1(2): April-June 2011; Page 28-33.

64. KumbharSwapnil, Salunkhe Vijay, MagdumChandrakant. Targeted Drug Delivery: A Backbone for Cancer Therapy. Asian J. Pharm. Res. 3(1): Jan.-Mar. 2013; Page 40-46.

65. Cai XR, Li X, Lin JX, Wang TT, Dong M, Chen ZH, Jia CC, Hong YF, Lin Q, Wu XY. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review. Oncotarget. 2017 May 9;8(19):31318-31328. doi: 10.18632/oncotarget.15454.

66. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J ClinOncol. 2018 Feb 1;48(2):103-114. doi: 10.1093/jjco/hyx180.

67. Kuol N, Stojanovska L, Nurgali K, Apostolopoulos V. PD-1/PD-L1 in disease. Immunotherapy. 2018 Feb;10(2):149-160. doi: 10.2217/imt-2017-0120.

68. Cheng H, Sun G, Chen H, Li Y, Han Z, Li Y, et al; Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019 Aug 1;9(8):1536-1545.

69. Doherty DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review. J Autoimmun. 2016 Jan;66:60-75. doi: 10.1016/j.jaut.2015.08.020.

Received on 31.10.2022 Modified on 24.11.2022

Asian J. Res. Pharm. Sci. 2023; 13(2):171-179.

DOI: 10.52711/2231-5659.2023.00030